New Generation Cooperative and Cognitive Dual Satellite Systems: Performance Evaluation

Investigating innovative satellite architectures with enhanced system through- put is one of the most important challenges towards realizing the next generation of satellite communication systems. In this context, we study two advanced architectures, namely cooperative and cognitive satellite systems. These designs allow the spectral coexistence of two multibeam satellites over a common coverage area with the overlapping beam patterns. In the cooperative dual satellite system, we consider coordination between two coexisting transmitters in order to reduce the intersatellite interference. This is achieved by employing adequate user scheduling, based on the channel state information of each user. To this end, a semi-orthogonal interference aware scheduling algorithm is applied. Further, in the cognitive dual satellite system, we employ a cognitive beamhopping technique assuming that the secondary gateway is aware of the primary's beamhopping pattern. Moreover, we compare the performances of these schemes with those of the conventional multi- beam and overlapping dual satellite systems in terms of spectral efficiency, power efficiency and user fairness. Finally, we provide several insights on the performance of these schemes and provide interesting future works in these domains

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Development of on package indicator sensor for real-time monitoring of meat quality

Aim: The aim was to develop an indicator sensor for real-time monitoring of meat quality and to compare the response of indicator sensor with meat quality parameters at ambient temperature. Materials and Methods: Indicator sensor was prepared using bromophenol blue (1% w/v) as indicator solution and filter paper as indicator carrier. Indicator sensor was fabricated by coating indicator solution onto carrier by centrifugation. To observe the response of indicator sensor buffalo meat was packed in polystyrene foam trays covered with PVC film and indicator sensor was attached to the inner side of packaging film. The pattern of color change in indicator sensor was monitored and compared with meat quality parameters viz. total volatile basic nitrogen, D-glucose, standard plate count and tyrosine value to correlate ability of indicator sensor for its suitability to predict the meat quality and storage life. Results: The indicator sensor changed its color from yellow to blue starting from margins during the storage period of 24 h at ambient temperature and this correlated well with changes in meat quality parameters. Conclusions: The indicator sensor can be used for real-time monitoring of meat quality as the color of indicator sensor changed from yellow to blue starting from margins when meat deteriorates with advancement of the storage period. Thus by observing the color of indicator sensor quality of meat and shelf life can be predicted

Not Available

Not AvailableComparison of quality and shelf life of buffalo meat patties stored at refrigeration temperature.Not Availabl

Not Available

Not AvailableThis work explores the efficacy and potential of four different blends of essential oils as bio-preservative for enhancement of shelf life of emulsion based ready-to-eat chicken sausages. Pre-optimized levels of four different blends of essential oils: 0.25% each of B-1, B-2, B-3 and 0.125% of B-4, were tried in the chicken sausages. Four different treatments along with control were then aerobically packaged and stored under refrigerated (4 ± 1 °C) conditions. An increase in pH and TBARS value was found to be significantly lower in the case of B-2 products. Significantly higher values for DPPH activity (% inhibition) and total phenolic content (µg/g) were also observed for B-2 products which indicated that B-2 products had better oxidative stability. Further, B-1 and B-2 products were observed with significantly lower microbial count; however, B-4 products received slightly higher sensory scores than B-2. It was found that B-1, 2 and 3 (each at 0.25%) and B-4 (0.125%) enhanced the shelf life of chicken sausages by 13–14 days, 16–17 days, 10–11 days and 6–7 days, respectively under refrigerated (4 ± 1 °C) storage.Not Availabl

Profile of Bioactive Phyto-compounds in Essential Oil of Cymbopogon martinii from Palani Hills, Western Ghats, INDIA

Worldwide interest in use of plants based natural products (PBNPs) has been growing, and its beneficial effects being rediscovered for the development of novel drugs. Literature survey on indigenous traditional knowledge bestows ethnopharmacological potentials of PBNPs that has inspired current research in drug design and discovery; PBNPs provide baseline for the development of novel drug leads against various pharmacological targets. Studies indicate that Cymbopogon martini Essential Oil (CMEO) exhibit wide range of biological activities such as hepatoprotective, antifungal, insecticide, antioxidant and antibacterial. Pharmacological properties in Palmarosa Essential Oil (PEO) may be due to the presence of compounds like 4-Decen-6-yne, (Z), 2-Ethylimino-4-methyl-pent-3-enenitrile, Dihydrocarvyl acetate, 2-Methylbenzaldehyde, Geranyl butyrate, 1,5,9,9-Tetramethyl-1,4,7-cycloundecatriene. However, its application is limited because of the odor, color and taste. In the present study, GCMS based profile of bioactive phyto-compounds in essential oil of Cymbopogon martinii along with its physiochemical, biological, molecular, pharmacological and drugable properties has been envisaged. Keywords: Cymbopogon martinii Essential Oil (CMEO); Pharmacological Activity; ADMET Properties; Bioactive Compounds; Plant Based Natural Products (PBNPs)

Serotyping of Salmonella strains isolated in and around Madurai, India

Abstract This study was carried out since there is a deep rooted interest in the accuracy of laboratory diagnosis and to predict the extent of typhi infection in Madurai area, Tamil Nadu, India. Cultures were identified by standard methods. Salmonella typhi was the more frequent serotype isolated (i.e.) 94% with the remaining 6% being Salmonella paratyphi. A total of 100 samples from diarrheic symptom persons were processed for the isolation of Salmonella. All the isolates were subjected to antimicrobial sensitivity tests and serotyping. Out of 100 samples 65% was obtained typhoid positive, among 61% Salmonella typhi and 4% S.paratyphi were obtained. Ceftrioxone, ciprofloxacin, cefunoxine were most effective while oflaxacin and chloromphenicol were least effective. Our finding shows that Salmonella typhi was predominantly found. For typhoid control measures were suggested to follow by proper treated drinking water

Physicochemical, ADMET and Druggable properties of Myricetin: A Key Flavonoid in Syzygium cumini that regulates metabolic inflammations

Syzygium cumini (Myrtaceae) is a potential medicinal plant traditionally used in indigenous systems of medicines practiced in India and elsewhere due to its functional properties against metabolic inflammations viz., anti-hyperglycemic, anti-inflammatory, cardio-protective, and antioxidant activities. Targeting metabolic inflammation has emerged as a standalone strategy to attenuate metabolic disease. Myricetin (3,5,7,3′,4′,5′-hexahydroxyflavone) is one of the flavonoids from stem bark, leaf, flowers, fruits, pulp and seeds of S. cumini. Therefore, attention has been paid to explore bioactive potentials of this compound in S. cumini owing to its exemplary therapeutic prospective and health-promoting effects. Antioxidant effect of Myricetin from S. cumini has been though experimentally demonstrated, therapeutic potential of Myricetin has not been fully explored. In the present study, physicochemical, ADMET and druggability properties of Myricetin - a key flavonoid compound in S. cumini have been evaluated. Data implicates that this molecule of GRAS standard can be a novel jumble-sale lead in drug discovery. Keywords: Plant Based Natural Products (PBNPs); Drug Discovery; Pharmacological Activity; ADMET Properties; Flavonoid; Myricetin; Syzygium cumin